Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang(Ariadne Diagnostics (United States)), Victor M. Rivera(Ariadne Diagnostics (United States))
Cited by 0
Related Papers
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
|Clinical Cancer Research|2016|325
N-myc downstream-regulated gene 1 inhibits the proliferation of colorectal cancer through emulative antagonizing NEDD4-mediated ubiquitylation of p21
|Journal of Experimental & Clinical Cancer Research|2019|48
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
|International Journal of Oncology|2012|31